Loading...

Figlin Robert

TitleProfessor
InstitutionUniversity of California Los Angeles
DepartmentMedicine
Address2333 PVUB
CAMPUS - 705907
Phone(310) 825-5788
vCardDownload vCard
    Other Positions
    TitleMedical Director


    Collapse Research 
    Collapse Research Activities and Funding
    UCLA/JCCC--SOUTHWEST ONCOLOGY GROUP
    NIH/NCI U10CA058348Feb 5, 1993 - Dec 31, 2003
    Role: Co-Principal Investigator
    City of Hope Clinical Oncology Career Research Development Program
    NIH/NCI K12CA001727Sep 9, 1992 - Jul 31, 2020
    Role: Co-Principal Investigator
    Cancer Center Support Grant
    NIH/NCI P30CA033572Jul 1, 1981 - Nov 30, 2023
    Role: Co-Principal Investigator

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Rini BI, Hutson TE, Figlin R, Lechuga MJ, Valota O, Serfass L, Rosbrook B, Motzer RJ. Sunitinib in Patients With Metastatic Renal Cell Carcinoma: Clinical Outcome According to International Metastatic Renal Cell Carcinoma Database Consortium Risk Group. Clin Genitourin Cancer. 2018 May 04. PMID: 29853320.
      View in: PubMed
    2. Figlin R. Highlights in renal cell carcinoma from the Sixteenth International Kidney Cancer Symposium: commentary. Clin Adv Hematol Oncol. 2018 Jan; 16 Suppl 1(1):21-23. PMID: 29742094.
      View in: PubMed
    3. Courtney KD, Infante JR, Lam ET, Figlin R, Rini BI, Brugarolas J, Zojwalla NJ, Lowe AM, Wang K, Wallace EM, Josey JA, Choueiri TK. Phase I Dose-Escalation Trial of PT2385, a First-in-Class Hypoxia-Inducible Factor-2a Antagonist in Patients With Previously Treated Advanced Clear Cell Renal Cell Carcinoma. J Clin Oncol. 2018 Mar 20; 36(9):867-874. PMID: 29257710.
      View in: PubMed
    4. Gresham G, Schrack J, Gresham LM, Shinde AM, Hendifar AE, Tuli R, Rimel BJ, Figlin R, Meinert CL, Piantadosi S. Wearable activity monitors in oncology trials: Current use of an emerging technology. Contemp Clin Trials. 2018 Jan; 64:13-21. PMID: 29129704.
      View in: PubMed
    5. Stewart GD, Leibovich BC, Negrier S, Figlin R. Adjuvant Pazopanib Does Not PROTECT Against Recurrence of High-Risk, Initially Localized Renal Cell Cancer but Does Provide Novel Insights. J Clin Oncol. 2017 Dec 10; 35(35):3895-3897. PMID: 29068785.
      View in: PubMed
    6. Ing N, Huang F, Conley A, You S, Ma Z, Klimov S, Ohe C, Yuan X, Amin MB, Figlin R, Gertych A, Knudsen BS. A novel machine learning approach reveals latent vascular phenotypes predictive of renal cancer outcome. Sci Rep. 2017 Oct 16; 7(1):13190. PMID: 29038551.
      View in: PubMed
    7. Posadas EM, Limvorasak S, Figlin R. Targeted therapies for renal cell carcinoma. Nat Rev Nephrol. 2017 Aug; 13(8):496-511. PMID: 28691713.
      View in: PubMed
    8. Tannir NM, Figlin R, Gore ME, Michaelson MD, Motzer RJ, Porta C, Rini BI, Hoang C, Lin X, Escudier B. Long-Term Response to Sunitinib Treatment in Metastatic Renal Cell Carcinoma: A Pooled Analysis of Clinical Trials. Clin Genitourin Cancer. 2017 Jun 20. PMID: 28711490.
      View in: PubMed
    9. Lakdawalla DN, Shafrin J, Hou N, Peneva D, Vine S, Park J, Zhang J, Brookmeyer R, Figlin R. Predicting Real-World Effectiveness of Cancer Therapies Using Overall Survival and Progression-Free Survival from Clinical Trials: Empirical Evidence for the ASCO Value Framework. Value Health. 2017 Jul - Aug; 20(7):866-875. PMID: 28712615.
      View in: PubMed
    10. Motzer RJ, Figlin R, Martini JF, Hariharan S, Agarwal N, Li CX, Williams JA, Hutson TE. Germline Genetic Biomarkers of Sunitinib Efficacy in Advanced Renal Cell Carcinoma: Results From the RENAL EFFECT Trial. Clin Genitourin Cancer. 2017 Oct; 15(5):526-533. PMID: 28330808.
      View in: PubMed
    11. Chen JF, Lu YT, Cheng S, Tseng HR, Figlin R, Posadas EM. Circulating tumor cells in prostate cancer: beyond enumeration. Clin Adv Hematol Oncol. 2017 Jan; 15(1):63-73. PMID: 28212371.
      View in: PubMed
    12. Kumbla RA, Figlin R, Posadas EM. Recent Advances in the Medical Treatment of Recurrent or Metastatic Renal Cell Cancer. Drugs. 2017 Jan; 77(1):17-28. PMID: 27995579.
      View in: PubMed
    13. Rini BI, McDermott DF, Hammers H, Bro W, Bukowski RM, Faba B, Faba J, Figlin R, Hutson T, Jonasch E, Joseph RW, Leibovich BC, Olencki T, Pantuck AJ, Quinn DI, Seery V, Voss MH, Wood CG, Wood LS, Atkins MB. Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of renal cell carcinoma. J Immunother Cancer. 2016; 4:81. PMID: 27891227.
      View in: PubMed
    14. Motzer RJ, Escudier B, Gannon A, Figlin R. Sunitinib: Ten Years of Successful Clinical Use and Study in Advanced Renal Cell Carcinoma. Oncologist. 2017 01; 22(1):41-52. PMID: 27807302.
      View in: PubMed
    15. Patel DN, Figlin R, Kim HL. Adjuvant treatment for renal cell carcinoma: do we finally have a major breakthrough? Clin Adv Hematol Oncol. 2016 Nov; 14(11):907-914. PMID: 27930642.
      View in: PubMed
    16. Posadas EM, Limvorasak S, Figlin R. Third-Line Treatment Options for Kidney Cancer. Oncology (Williston Park). 2016 09 15; 30(9):813-5. PMID: 27633411.
      View in: PubMed
    17. Sella A, Michaelson MD, Matczak E, Simantov R, Lin X, Figlin R. Heterogeneity of Patients With Intermediate-Prognosis Metastatic Renal Cell Carcinoma Treated With Sunitinib. Clin Genitourin Cancer. 2017 04; 15(2):291-299.e1. PMID: 27638198.
      View in: PubMed
    18. Posadas EM, Figlin R. Personalized Therapeutics and Value in Renal Cell Carcinoma: Moving Beyond Lines of Therapy. J Oncol Pract. 2016 05; 12(5):424-5. PMID: 27170689.
      View in: PubMed
    19. Bono P, Oudard S, Bodrogi I, Hutson TE, Escudier B, Machiels JP, Thompson JA, Figlin R, Ravaud A, Basaran M, Porta C, Bracarda S, Brechenmacher T, Lin C, Voi M, Grunwald V, Motzer RJ. Outcomes in Patients With Metastatic Renal Cell Carcinoma Who Develop Everolimus-Related Hyperglycemia and Hypercholesterolemia: Combined Subgroup Analyses of the RECORD-1 and REACT Trials. Clin Genitourin Cancer. 2016 10; 14(5):406-414. PMID: 27287020.
      View in: PubMed
    20. Shafrin J, Brookmeyer R, Peneva D, Park J, Zhang J, Figlin R, Lakdawalla DN. The value of surrogate endpoints for predicting real-world survival across five cancer types. Curr Med Res Opin. 2016; 32(4):731-9. PMID: 26743800.
      View in: PubMed
    21. Banerjee N, Sachdev E, Figlin R. A Rare Finding of a BRAF Mutation in Renal Cell Carcinoma with Response to BRAF-Directed Targeted Therapy. Cureus. 2016 Jan 06; 8(1):e449. PMID: 26918217; PMCID: PMC4744077.
    22. Hutson TE, Thoreson GR, Figlin R, Rini BI. The Evolution of Systemic Therapy in Metastatic Renal Cell Carcinoma. Am Soc Clin Oncol Educ Book. 2016; 35:113-7. PMID: 27249692.
      View in: PubMed
    23. Goldstein D, Rosenberg JE, Figlin R, Townsend RR, McCann L, Carpenter C, Pandite L. Is change in blood pressure a biomarker of pazopanib and sunitinib efficacy in advanced/metastatic renal cell carcinoma? Eur J Cancer. 2016 Jan; 53:96-104. PMID: 26702763.
      View in: PubMed
    24. Pal SK, Vuong W, Zhang W, Deng J, Liu X, Carmichael C, Ruel N, Pinnamaneni M, Twardowski P, Lau C, Yu H, Figlin R, Agarwal N, Jones JO. Clinical and Translational Assessment of VEGFR1 as a Mediator of the Premetastatic Niche in High-Risk Localized Prostate Cancer. Mol Cancer Ther. 2015 Dec; 14(12):2896-900. PMID: 26450920.
      View in: PubMed
    25. Figlin R. Personalized immunotherapy ( AGS-003 ) when combined with sunitinib for the treatment of metastatic renal cell carcinoma. Expert Opin Biol Ther. 2015; 15(8):1241-8. PMID: 26125651.
      View in: PubMed
    26. Reckamp KL, Koczywas M, Cristea MC, Dowell JE, Wang HJ, Gardner BK, Milne GL, Figlin R, Fishbein MC, Elashoff RM, Dubinett SM. Randomized phase 2 trial of erlotinib in combination with high-dose celecoxib or placebo in patients with advanced non-small cell lung cancer. Cancer. 2015 Sep 15; 121(18):3298-306. PMID: 26033830; PMCID: PMC4864011.
    27. Amin A, Dudek AZ, Logan TF, Lance RS, Holzbeierlein JM, Knox JJ, Master VA, Pal SK, Miller WH, Karsh LI, Tcherepanova IY, DeBenedette MA, Williams WL, Plessinger DC, Nicolette CA, Figlin R. Survival with AGS-003, an autologous dendritic cell-based immunotherapy, in combination with sunitinib in unfavorable risk patients with advanced renal cell carcinoma (RCC): Phase 2 study results. J Immunother Cancer. 2015; 3:14. PMID: 25901286; PMCID: PMC4404644.
    28. Pal SK, Bergerot P, Figlin R. Renal cell carcinoma: An update for the practicing urologist. Asian J Urol. 2015 Jan; 2(1):19-25. PMID: 29264115.
      View in: PubMed
    29. McDermott DF, Cheng SC, Signoretti S, Margolin KA, Clark JI, Sosman JA, Dutcher JP, Logan TF, Curti BD, Ernstoff MS, Appleman L, Wong MK, Khushalani NI, Oleksowicz L, Vaishampayan UN, Mier JW, Panka DJ, Bhatt RS, Bailey AS, Leibovich BC, Kwon ED, Kabbinavar FF, Belldegrun AS, Figlin R, Pantuck AJ, Regan MM, Atkins MB. The high-dose aldesleukin "select" trial: a trial to prospectively validate predictive models of response to treatment in patients with metastatic renal cell carcinoma. Clin Cancer Res. 2015 Feb 01; 21(3):561-8. PMID: 25424850; PMCID: PMC4315731.
    30. Motzer RJ, Hutson TE, Hudes GR, Figlin R, Martini JF, English PA, Huang X, Valota O, Williams JA. Investigation of novel circulating proteins, germ line single-nucleotide polymorphisms, and molecular tumor markers as potential efficacy biomarkers of first-line sunitinib therapy for advanced renal cell carcinoma. Cancer Chemother Pharmacol. 2014 Oct; 74(4):739-50. PMID: 25100134; PMCID: PMC4175044.
    31. Posadas EM, Figlin R. Kidney cancer: progress and controversies in neoadjuvant therapy. Nat Rev Urol. 2014 May; 11(5):254-5. PMID: 24752207.
      View in: PubMed
    32. Forscher C, Mita M, Figlin R. Targeted therapy for sarcomas. Biologics. 2014; 8:91-105. PMID: 24669185; PMCID: PMC3962319.
    33. Cella D, Davis MP, Négrier S, Figlin R, Michaelson MD, Bushmakin AG, Cappelleri JC, Sandin R, Korytowsky B, Charbonneau C, Matczak E, Motzer RJ. Characterizing fatigue associated with sunitinib and its impact on health-related quality of life in patients with metastatic renal cell carcinoma. Cancer. 2014 Jun 15; 120(12):1871-80. PMID: 24634003; PMCID: PMC4231253.
    34. Pal SK, Figlin R. Ramucirumab in metastatic renal cell carcinoma: The beginning or the end? Cancer. 2014 Jun 01; 120(11):1604-7. PMID: 24577887.
      View in: PubMed
    35. Wang Y, Sparwasser T, Figlin R, Kim HL. Foxp3+ T cells inhibit antitumor immune memory modulated by mTOR inhibition. Cancer Res. 2014 Apr 15; 74(8):2217-28. PMID: 24574514.
      View in: PubMed
    36. Pal SK, Hu A, Chang M, Figlin R. Programmed death-1 inhibition in renal cell carcinoma: clinical insights and future directions. Clin Adv Hematol Oncol. 2014 Feb; 12(2):90-9. PMID: 24892254.
      View in: PubMed
    37. Figlin R. A novel personalized vaccine approach in combination with targeted therapy in advanced renal cell carcinoma. Immunotherapy. 2014; 6(3):261-8. PMID: 24354908.
      View in: PubMed
    38. Rosenberg JE, Bambury RM, Van Allen EM, Drabkin HA, Lara PN, Harzstark AL, Wagle N, Figlin R, Smith GW, Garraway LA, Choueiri T, Erlandsson F, Laber DA. A phase II trial of AS1411 (a novel nucleolin-targeted DNA aptamer) in metastatic renal cell carcinoma. Invest New Drugs. 2014 Feb; 32(1):178-87. PMID: 24242861; PMCID: PMC4560460.
    39. Harmon CS, DePrimo SE, Figlin R, Hudes GR, Hutson TE, Michaelson MD, Négrier S, Kim ST, Huang X, Williams JA, Eisen T, Motzer RJ. Circulating proteins as potential biomarkers of sunitinib and interferon-a efficacy in treatment-naïve patients with metastatic renal cell carcinoma. Cancer Chemother Pharmacol. 2014 Jan; 73(1):151-61. PMID: 24220935; PMCID: PMC3889677.
    40. Posadas EM, Limvorasak S, Sharma S, Figlin R. Targeting angiogenesis in renal cell carcinoma. Expert Opin Pharmacother. 2013 Nov; 14(16):2221-36. PMID: 23984807.
      View in: PubMed
    41. Pal SK, Hu A, Figlin R. A new age for vaccine therapy in renal cell carcinoma. Cancer J. 2013 Jul-Aug; 19(4):365-70. PMID: 23867519; PMCID: PMC3845885.
    42. Zhang W, Pal SK, Liu X, Yang C, Allahabadi S, Bhanji S, Figlin R, Yu H, Reckamp KL. Myeloid clusters are associated with a pro-metastatic environment and poor prognosis in smoking-related early stage non-small cell lung cancer. PLoS One. 2013; 8(5):e65121. PMID: 23717691; PMCID: PMC3663795.
    43. Pal SK, Hsu J, Hsu S, Hu J, Bergerot P, Carmichael C, Saikia J, Liu X, Lau C, Twardowski P, Figlin R, Yuh BF. Impact of age on treatment trends and clinical outcome in patients with metastatic renal cell carcinoma. J Geriatr Oncol. 2013 Apr; 4(2):128-33. PMID: 23646100.
      View in: PubMed
    44. Figlin R, Kaufmann I, Brechbiel J. Targeting PI3K and mTORC2 in metastatic renal cell carcinoma: new strategies for overcoming resistance to VEGFR and mTORC1 inhibitors. Int J Cancer. 2013 Aug 15; 133(4):788-96. PMID: 23319457.
      View in: PubMed
    45. Zhang H, Berel D, Wang Y, Li P, Bhowmick NA, Figlin R, Kim HL. A comparison of Ku0063794, a dual mTORC1 and mTORC2 inhibitor, and temsirolimus in preclinical renal cell carcinoma models. PLoS One. 2013; 8(1):e54918. PMID: 23349989; PMCID: PMC3551765.
    46. Figlin R. Tivozanib in renal cell carcinoma. Clin Adv Hematol Oncol. 2013 Jan; 11(1):43-5. PMID: 23416862.
      View in: PubMed
    47. Posadas EM, Figlin R. Understanding the role of MET kinase in cancer therapy. J Clin Oncol. 2013 Jan 10; 31(2):169-70. PMID: 23213104.
      View in: PubMed
    48. Mita AC, Figlin R, Mita MM. Cabazitaxel: more than a new taxane for metastatic castrate-resistant prostate cancer? Clin Cancer Res. 2012 Dec 15; 18(24):6574-9. PMID: 23091116.
      View in: PubMed
    49. Pal SK, Bergerot PG, Figlin R. Tivozanib: current status and future directions in the treatment of solid tumors. Expert Opin Investig Drugs. 2012 Dec; 21(12):1851-9. PMID: 23013465; PMCID: PMC3934561.
    50. Figlin R, Sternberg C, Wood CG. Novel agents and approaches for advanced renal cell carcinoma. J Urol. 2012 Sep; 188(3):707-15. PMID: 22818130.
      View in: PubMed
    51. Tran HT, Liu Y, Zurita AJ, Lin Y, Baker-Neblett KL, Martin AM, Figlin R, Hutson TE, Sternberg CN, Amado RG, Pandite LN, Heymach JV. Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials. Lancet Oncol. 2012 Aug; 13(8):827-37. PMID: 22759480.
      View in: PubMed
    52. Cho DC, Hutson TE, Samlowski W, Sportelli P, Somer B, Richards P, Sosman JA, Puzanov I, Michaelson MD, Flaherty KT, Figlin R, Vogelzang NJ. Two phase 2 trials of the novel Akt inhibitor perifosine in patients with advanced renal cell carcinoma after progression on vascular endothelial growth factor-targeted therapy. Cancer. 2012 Dec 15; 118(24):6055-62. PMID: 22674198; PMCID: PMC3934426.
    53. Wu X, Weng L, Li X, Guo C, Pal SK, Jin JM, Li Y, Nelson RA, Mu B, Onami SH, Wu JJ, Ruel NH, Wilczynski SP, Gao H, Covarrubias M, Figlin R, Weiss LM, Wu H. Identification of a 4-microRNA signature for clear cell renal cell carcinoma metastasis and prognosis. PLoS One. 2012; 7(5):e35661. PMID: 22623952; PMCID: PMC3356334.
    54. Pal SK, Jones JO, Carmichael C, Saikia J, Hsu J, Liu X, Figlin R, Twardowski P, Lau C. Clinical outcome in patients receiving systemic therapy for metastatic sarcomatoid renal cell carcinoma: a retrospective analysis. Urol Oncol. 2013 Nov; 31(8):1826-31. PMID: 22608544; PMCID: PMC3529212.
    55. Deng J, Liu Y, Lee H, Herrmann A, Zhang W, Zhang C, Shen S, Priceman SJ, Kujawski M, Pal SK, Raubitschek A, Hoon DS, Forman S, Figlin R, Liu J, Jove R, Yu H. S1PR1-STAT3 signaling is crucial for myeloid cell colonization at future metastatic sites. Cancer Cell. 2012 May 15; 21(5):642-54. PMID: 22624714; PMCID: PMC3360884.
    56. Motzer RJ, Hutson TE, Olsen MR, Hudes GR, Burke JM, Edenfield WJ, Wilding G, Agarwal N, Thompson JA, Cella D, Bello A, Korytowsky B, Yuan J, Valota O, Martell B, Hariharan S, Figlin R. Randomized phase II trial of sunitinib on an intermittent versus continuous dosing schedule as first-line therapy for advanced renal cell carcinoma. J Clin Oncol. 2012 Apr 20; 30(12):1371-7. PMID: 22430274.
      View in: PubMed
    57. Posadas EM, Figlin R. Systemic therapy in renal cell carcinoma: advancing paradigms. Oncology (Williston Park). 2012 Mar; 26(3):290-301. PMID: 22545314.
      View in: PubMed
    58. Benz MR, Herrmann K, Walter F, Garon EB, Reckamp KL, Figlin R, Phelps ME, Weber WA, Czernin J, Allen-Auerbach MS. (18)F-FDG PET/CT for monitoring treatment responses to the epidermal growth factor receptor inhibitor erlotinib. J Nucl Med. 2011 Nov; 52(11):1684-1689. PMID: 22045706; PMCID: PMC5021512.
    59. Xin H, Herrmann A, Reckamp K, Zhang W, Pal S, Hedvat M, Zhang C, Liang W, Scuto A, Weng S, Morosini D, Cao ZA, Zinda M, Figlin R, Huszar D, Jove R, Yu H. Antiangiogenic and antimetastatic activity of JAK inhibitor AZD1480. Cancer Res. 2011 Nov 01; 71(21):6601-10. PMID: 21920898; PMCID: PMC3206173.
    60. Pal SK, Vanderwalde A, Hurria A, Figlin R. Systemic therapies for metastatic renal cell carcinoma in older adults. Drugs Aging. 2011 Aug 01; 28(8):635-49. PMID: 21812499.
      View in: PubMed
    61. Pal SK, Figlin R. Unraveling the role of hypoxia-inducible factor in renal cell carcinoma: a biological and therapeutic perspective. Cancer Discov. 2011 Aug; 1(3):198-9. PMID: 22586568.
      View in: PubMed
    62. Rini BI, Cohen DP, Lu DR, Chen I, Hariharan S, Gore ME, Figlin R, Baum MS, Motzer RJ. Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst. 2011 May 04; 103(9):763-73. PMID: 21527770; PMCID: PMC3086879.
    63. Pal SK, Figlin R. Future directions of mammalian target of rapamycin (mTOR) inhibitor therapy in renal cell carcinoma. Target Oncol. 2011 Mar; 6(1):5-16. PMID: 21484496; PMCID: PMC3253822.
    64. Benedict A, Figlin R, Sandström P, Harmenberg U, Ullén A, Charbonneau C, Sandin R, Remák E, Hariharan S, Négrier S. Economic evaluation of new targeted therapies for the first-line treatment of patients with metastatic renal cell carcinoma. BJU Int. 2011 Sep; 108(5):665-72. PMID: 21265994.
      View in: PubMed
    65. Lee H, Pal SK, Reckamp K, Figlin R, Yu H. STAT3: a target to enhance antitumor immune response. Curr Top Microbiol Immunol. 2011; 344:41-59. PMID: 20517723; PMCID: PMC3244828.
    66. Kujawski M, Zhang C, Herrmann A, Reckamp K, Scuto A, Jensen M, Deng J, Forman S, Figlin R, Yu H. Targeting STAT3 in adoptively transferred T cells promotes their in vivo expansion and antitumor effects. Cancer Res. 2010 Dec 01; 70(23):9599-610. PMID: 21118964; PMCID: PMC3017475.
    67. Pal SK, Kortylewski M, Yu H, Figlin R. Breaking through a plateau in renal cell carcinoma therapeutics: development and incorporation of biomarkers. Mol Cancer Ther. 2010 Dec; 9(12):3115-25. PMID: 21078774; PMCID: PMC3244352.
    68. Pal SK, Figlin R. Bevacizumab for metastatic renal cell carcinoma: a monoclonal antibody in a sea of small molecules. Expert Opin Biol Ther. 2010 Nov; 10(11):1517-20. PMID: 20955110.
      View in: PubMed
    69. Pal SK, Figlin R, Yu H. Deciphering the anticancer mechanisms of sunitinib. Cancer Biol Ther. 2010 Oct 01; 10(7):712-4. PMID: 20716960; PMCID: PMC3093811.
    70. Pal SK, Reckamp K, Yu H, Figlin R. Akt inhibitors in clinical development for the treatment of cancer. Expert Opin Investig Drugs. 2010 Nov; 19(11):1355-66. PMID: 20846000; PMCID: PMC3244346.
    71. Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, Grünwald V, Thompson JA, Figlin R, Hollaender N, Kay A, Ravaud A. Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors. Cancer. 2010 Sep 15; 116(18):4256-65. PMID: 20549832.
      View in: PubMed
    72. Herrmann A, Kortylewski M, Kujawski M, Zhang C, Reckamp K, Armstrong B, Wang L, Kowolik C, Deng J, Figlin R, Yu H. Targeting Stat3 in the myeloid compartment drastically improves the in vivo antitumor functions of adoptively transferred T cells. Cancer Res. 2010 Oct 01; 70(19):7455-64. PMID: 20841481; PMCID: PMC3058618.
    73. Wiesner C, Hannum C, Reckamp K, Figlin R, Dubridge R, Roy SM, Lin S, Becker CH, Jones T, Hiller J, Cheville JC, Wilson K. Consistency of a two clinical site sample collection: a proteomics study. Proteomics Clin Appl. 2010 Sep; 4(8-9):726-38. PMID: 21137090.
      View in: PubMed
    74. Bukowski RM, Stadler WM, McDermott DF, Dutcher JP, Knox JJ, Miller WH, Hainsworth JD, Henderson CA, Hajdenberg J, Kindwall-Keller TL, Ernstoff MS, Drabkin HA, Curti BD, Chu L, Ryan CW, Hotte SJ, Xia C, Cupit L, Figlin R. Safety and efficacy of sorafenib in elderly patients treated in the North American advanced renal cell carcinoma sorafenib expanded access program. Oncology. 2010; 78(5-6):340-7. PMID: 20733337.
      View in: PubMed
    75. Hutson TE, Bukowski RM, Cowey CL, Figlin R, Escudier B, Sternberg CN. Sequential use of targeted agents in the treatment of renal cell carcinoma. Crit Rev Oncol Hematol. 2011 Jan; 77(1):48-62. PMID: 20705477.
      View in: PubMed
    76. Pal SK, Figlin R. Targeted therapies for renal cell carcinoma: understanding their impact on survival. Target Oncol. 2010 Jun; 5(2):131-8. PMID: 20632214.
      View in: PubMed
    77. Pal SK, Figlin R. Targeted therapies: Pazopanib: carving a niche in a crowded therapeutic landscape. Nat Rev Clin Oncol. 2010 Jul; 7(7):362-3. PMID: 20592710.
      View in: PubMed
    78. Pal SK, Figlin R, Reckamp K. Targeted therapies for non-small cell lung cancer: an evolving landscape. Mol Cancer Ther. 2010 Jul; 9(7):1931-44. PMID: 20571071; PMCID: PMC3244351.
    79. Pal SK, Figlin R. Treatment Options in Metastatic Renal Cell Carcinoma: Focus on mTOR Inhibitors. Clin Med Insights Oncol. 2010 Jun 09; 4:43-53. PMID: 20711245; PMCID: PMC2902205.
    80. Pal SK, Figlin R. Renal cell carcinoma therapy in 2010: many options with little comparative data. Clin Adv Hematol Oncol. 2010 Mar; 8(3):191-200. PMID: 20400934.
      View in: PubMed
    81. Stadler WM, Figlin R, McDermott DF, Dutcher JP, Knox JJ, Miller WH, Hainsworth JD, Henderson CA, George JR, Hajdenberg J, Kindwall-Keller TL, Ernstoff MS, Drabkin HA, Curti BD, Chu L, Ryan CW, Hotte SJ, Xia C, Cupit L, Bukowski RM. Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America. Cancer. 2010 Mar 01; 116(5):1272-80. PMID: 20082451.
      View in: PubMed
    82. Hutson TE, Davis ID, Machiels JP, De Souza PL, Rottey S, Hong BF, Epstein RJ, Baker KL, McCann L, Crofts T, Pandite L, Figlin R. Efficacy and safety of pazopanib in patients with metastatic renal cell carcinoma. J Clin Oncol. 2010 Jan 20; 28(3):475-80. PMID: 20008644.
      View in: PubMed
    83. Porta C, Figlin R. Phosphatidylinositol-3-kinase/Akt signaling pathway and kidney cancer, and the therapeutic potential of phosphatidylinositol-3-kinase/Akt inhibitors. J Urol. 2009 Dec; 182(6):2569-77. PMID: 19836781.
      View in: PubMed
    84. Figlin R. Anti-angiogenic therapy in renal cell carcinoma: Alone, in combination, or sequentially. Clin Adv Hematol Oncol. 2009 Oct; 7(10):662-5. PMID: 20040906.
      View in: PubMed
    85. Kapoor A, Figlin R. Targeted inhibition of mammalian target of rapamycin for the treatment of advanced renal cell carcinoma. Cancer. 2009 Aug 15; 115(16):3618-30. PMID: 19479976.
      View in: PubMed
    86. Figlin R, de Souza P, McDermott D, Dutcher JP, Berkenblit A, Thiele A, Krygowski M, Strahs A, Feingold J, Boni J, Hudes G. Analysis of PTEN and HIF-1alpha and correlation with efficacy in patients with advanced renal cell carcinoma treated with temsirolimus versus interferon-alpha. Cancer. 2009 Aug 15; 115(16):3651-60. PMID: 19526589.
      View in: PubMed
    87. Reckamp KL, Figlin R, Burdick MD, Dubinett SM, Elashoff RM, Strieter RM. CXCR4 expression on circulating pan-cytokeratin positive cells is associated with survival in patients with advanced non-small cell lung cancer. BMC Cancer. 2009 Jun 29; 9:213. PMID: 19563666; PMCID: PMC2708193.
    88. Motzer RJ, Agarwal N, Beard C, Bolger GB, Boston B, Carducci MA, Choueiri TK, Figlin R, Fishman M, Hancock SL, Hudes GR, Jonasch E, Kessinger A, Kuzel TM, Lange PH, Levine EG, Margolin KA, Michaelson MD, Olencki T, Pili R, Redman BG, Robertson CN, Schwartz LH, Sheinfeld J, Wang J. NCCN clinical practice guidelines in oncology: kidney cancer. J Natl Compr Canc Netw. 2009 Jun; 7(6):618-30. PMID: 19555584.
      View in: PubMed
    89. Motzer RJ, Agarwal N, Beard C, Bolger GB, Boston B, Carducci MA, Choueiri TK, Figlin R, Fishman M, Hancock SL, Hudes GR, Jonasch E, Kessinger A, Kuzel TM, Lange PH, Levine EG, Margolin KA, Michaelson MD, Olencki T, Pili R, Redman BG, Robertson CN, Schwartz LH, Sheinfeld J, Wang J. NCCN clinical practice guidelines in oncology: testicular cancer. J Natl Compr Canc Netw. 2009 Jun; 7(6):672-93. PMID: 19555582.
      View in: PubMed
    90. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Oudard S, Negrier S, Szczylik C, Pili R, Bjarnason GA, Garcia-del-Muro X, Sosman JA, Solska E, Wilding G, Thompson JA, Kim ST, Chen I, Huang X, Figlin R. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol. 2009 Aug 01; 27(22):3584-90. PMID: 19487381; PMCID: PMC3646307.
    91. Atkins MB, Bukowski RM, Escudier BJ, Figlin R, Hudes GH, Kaelin WG, Linehan WM, McDermott DF, Mier JW, Pedrosa I, Rini BI, Signoretti S, Sosman JA, Teh BT, Wood CG, Zurita AJ, King L. Innovations and challenges in renal cancer: summary statement from the Third Cambridge Conference. Cancer. 2009 May 15; 115(10 Suppl):2247-51. PMID: 19402064.
      View in: PubMed
    92. Hutson TE, Figlin R. Novel therapeutics for metastatic renal cell carcinoma. Cancer. 2009 May 15; 115(10 Suppl):2361-7. PMID: 19402059.
      View in: PubMed
    93. Xin H, Zhang C, Herrmann A, Du Y, Figlin R, Yu H. Sunitinib inhibition of Stat3 induces renal cell carcinoma tumor cell apoptosis and reduces immunosuppressive cells. Cancer Res. 2009 Mar 15; 69(6):2506-13. PMID: 19244102; PMCID: PMC2664264.
    94. Dutcher JP, de Souza P, McDermott D, Figlin R, Berkenblit A, Thiele A, Krygowski M, Strahs A, Feingold J, Hudes G. Effect of temsirolimus versus interferon-alpha on outcome of patients with advanced renal cell carcinoma of different tumor histologies. Med Oncol. 2009; 26(2):202-9. PMID: 19229667.
      View in: PubMed
    95. Motzer RJ, Hudes G, Wilding G, Schwartz LH, Hariharan S, Kempin S, Fayyad R, Figlin R. Phase I trial of sunitinib malate plus interferon-alpha for patients with metastatic renal cell carcinoma. Clin Genitourin Cancer. 2009 Jan; 7(1):28-33. PMID: 19213665; PMCID: PMC3394091.
    96. Hutson TE, Figlin R. Experimental therapy for advanced renal cell carcinoma. Expert Opin Investig Drugs. 2008 Nov; 17(11):1693-702. PMID: 18922106.
      View in: PubMed
    97. Pal SK, Figlin R, Reckamp KL. The role of targeting mammalian target of rapamycin in lung cancer. Clin Lung Cancer. 2008 Nov; 9(6):340-5. PMID: 19073516.
      View in: PubMed
    98. Hutson TE, Figlin R, Kuhn JG, Motzer RJ. Targeted therapies for metastatic renal cell carcinoma: an overview of toxicity and dosing strategies. Oncologist. 2008 Oct; 13(10):1084-96. PMID: 18838439.
      View in: PubMed
    99. Motzer RJ, Bukowski RM, Figlin R, Hutson TE, Michaelson MD, Kim ST, Baum CM, Kattan MW. Prognostic nomogram for sunitinib in patients with metastatic renal cell carcinoma. Cancer. 2008 Oct 01; 113(7):1552-8. PMID: 18720362.
      View in: PubMed
    100. Figlin R, Brown E, Armstrong AJ, Akerley W, Benson AB, Burstein HJ, Ettinger DS, Febbo PG, Fury MG, Hudes GR, Kies MS, Kwak EL, Morgan RJ, Mortimer J, Reckamp K, Venook AP, Worden F, Yen Y. NCCN Task Force Report: mTOR inhibition in solid tumors. J Natl Compr Canc Netw. 2008 Sep; 6 Suppl 5:S1-20; quiz S21-2. PMID: 18926092.
      View in: PubMed
    101. Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, Grünwald V, Thompson JA, Figlin R, Hollaender N, Urbanowitz G, Berg WJ, Kay A, Lebwohl D, Ravaud A. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet. 2008 Aug 09; 372(9637):449-56. PMID: 18653228.
      View in: PubMed
    102. Figlin R. Mechanisms of Disease: survival benefit of temsirolimus validates a role for mTOR in the management of advanced RCC. Nat Clin Pract Oncol. 2008 Oct; 5(10):601-9. PMID: 18607393.
      View in: PubMed
    103. Wood C, Srivastava P, Bukowski R, Lacombe L, Gorelov AI, Gorelov S, Mulders P, Zielinski H, Hoos A, Teofilovici F, Isakov L, Flanigan R, Figlin R, Gupta R, Escudier B. An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trial. Lancet. 2008 Jul 12; 372(9633):145-54. PMID: 18602688.
      View in: PubMed
    104. Moldawer NP, Figlin R. Renal cell carcinoma: the translation of molecular biology into new treatments, new patient outcomes, and nursing implications. Oncol Nurs Forum. 2008 Jul; 35(4):699-708. PMID: 18591174.
      View in: PubMed
    105. Hurria A, Balducci L, Naeim A, Gross C, Mohile S, Klepin H, Tew W, Downey L, Gajra A, Owusu C, Sanati H, Suh T, Figlin R. Mentoring junior faculty in geriatric oncology: report from the Cancer and Aging Research Group. J Clin Oncol. 2008 Jul 01; 26(19):3125-7. PMID: 18591553; PMCID: PMC3622440.
    106. Jonasch E, Stadler WM, Bukowski RM, Hayes TG, Varadhachary A, Malik R, Figlin R, Srinivas S. Phase 2 trial of talactoferrin in previously treated patients with metastatic renal cell carcinoma. Cancer. 2008 Jul 01; 113(1):72-7. PMID: 18484647.
      View in: PubMed
    107. Twardowski P, Figlin R. Bevacizumab plus interferon alpha in patients with metastatic renal cell carcinoma. Nat Clin Pract Oncol. 2008 Aug; 5(8):436-7. PMID: 18560387.
      View in: PubMed
    108. Reckamp KL, Strieter RM, Figlin R. Chemokines as therapeutic targets in renal cell carcinoma. Expert Rev Anticancer Ther. 2008 Jun; 8(6):887-93. PMID: 18533798; PMCID: PMC2884168.
    109. Ettinger DS, Akerley W, Bepler G, Chang A, Cheney RT, Chirieac LR, D'Amico TA, Demmy TL, Feigenberg SJ, Figlin R, Govindan R, Grannis FW, Jahan T, Jahanzeb M, Kessinger A, Komaki R, Kris MG, Langer CJ, Le QT, Martins R, Otterson GA, Patel JD, Robert F, Sugarbaker DJ, Wood DE. Non-small cell lung cancer. J Natl Compr Canc Netw. 2008 Mar; 6(3):228-69. PMID: 18377844.
      View in: PubMed
    110. Reckamp KL, Gardner BK, Figlin R, Elashoff D, Krysan K, Dohadwala M, Mao J, Sharma S, Inge L, Rajasekaran A, Dubinett SM. Tumor response to combination celecoxib and erlotinib therapy in non-small cell lung cancer is associated with a low baseline matrix metalloproteinase-9 and a decline in serum-soluble E-cadherin. J Thorac Oncol. 2008 Feb; 3(2):117-24. PMID: 18303430.
      View in: PubMed
    111. Weiner LM, Belldegrun AS, Crawford J, Tolcher AW, Lockbaum P, Arends RH, Navale L, Amado RG, Schwab G, Figlin R. Dose and schedule study of panitumumab monotherapy in patients with advanced solid malignancies. Clin Cancer Res. 2008 Jan 15; 14(2):502-8. PMID: 18223225.
      View in: PubMed
    112. Ebbinghaus S, Hussain M, Tannir N, Gordon M, Desai AA, Knight RA, Humerickhouse RA, Qian J, Gordon GB, Figlin R. Phase 2 study of ABT-510 in patients with previously untreated advanced renal cell carcinoma. Clin Cancer Res. 2007 Nov 15; 13(22 Pt 1):6689-95. PMID: 18006769.
      View in: PubMed
    113. Figlin R. Temsirolimus for advanced renal cell carcinoma. Clin Adv Hematol Oncol. 2007 Nov; 5(11):893. PMID: 18185488.
      View in: PubMed
    114. Lam JS, Klatte T, Kim HL, Patard JJ, Breda A, Zisman A, Pantuck AJ, Figlin R. Prognostic factors and selection for clinical studies of patients with kidney cancer. Crit Rev Oncol Hematol. 2008 Mar; 65(3):235-62. PMID: 17931881.
      View in: PubMed
    115. Avigan DE, Vasir B, George DJ, Oh WK, Atkins MB, McDermott DF, Kantoff PW, Figlin R, Vasconcelles MJ, Xu Y, Kufe D, Bukowski RM. Phase I/II study of vaccination with electrofused allogeneic dendritic cells/autologous tumor-derived cells in patients with stage IV renal cell carcinoma. J Immunother. 2007 Oct; 30(7):749-61. PMID: 17893567.
      View in: PubMed
    116. Bukowski RM, Kabbinavar FF, Figlin R, Flaherty K, Srinivas S, Vaishampayan U, Drabkin HA, Dutcher J, Ryba S, Xia Q, Scappaticci FA, McDermott D. Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer. J Clin Oncol. 2007 Oct 10; 25(29):4536-41. PMID: 17876014.
      View in: PubMed
    117. Hutson TE, Figlin R. Evolving role of novel targeted agents in renal cell carcinoma. Oncology (Williston Park). 2007 Sep; 21(10):1175-80; discussion 1184, 1187, 1190. PMID: 17926797.
      View in: PubMed
    118. Hutson TE, Figlin R. Renal cell cancer. Cancer J. 2007 Sep-Oct; 13(5):282-6. PMID: 17921725.
      View in: PubMed
    119. Twardowski P, Figlin R. What are the indications for sorafenib treatment in patients with renal cell carcinoma? Nat Clin Pract Oncol. 2007 Aug; 4(8):456-7. PMID: 17579598.
      View in: PubMed
    120. Pantuck AJ, Seligson DB, Klatte T, Yu H, Leppert JT, Moore L, O'Toole T, Gibbons J, Belldegrun AS, Figlin R. Prognostic relevance of the mTOR pathway in renal cell carcinoma: implications for molecular patient selection for targeted therapy. Cancer. 2007 Jun 01; 109(11):2257-67. PMID: 17440983.
      View in: PubMed
    121. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, Sosman J, McDermott D, Bodrogi I, Kovacevic Z, Lesovoy V, Schmidt-Wolf IG, Barbarash O, Gokmen E, O'Toole T, Lustgarten S, Moore L, Motzer RJ. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007 May 31; 356(22):2271-81. PMID: 17538086.
      View in: PubMed
    122. Klatte T, Patard JJ, Goel RH, Kleid MD, Guille F, Lobel B, Abbou CC, De La Taille A, Tostain J, Cindolo L, Altieri V, Ficarra V, Artibani W, Prayer-Galetti T, Allhoff EP, Schips L, Zigeuner R, Figlin R, Kabbinavar FF, Pantuck AJ, Belldegrun AS, Lam JS. Prognostic impact of tumor size on pT2 renal cell carcinoma: an international multicenter experience. J Urol. 2007 Jul; 178(1):35-40; discussion 40. PMID: 17521678.
      View in: PubMed
    123. Reckamp KL, Figlin R, Moldawer N, Pantuck AJ, Belldegrun AS, Burdick MD, Strieter RM. Expression of CXCR3 on mononuclear cells and CXCR3 ligands in patients with metastatic renal cell carcinoma in response to systemic IL-2 therapy. J Immunother. 2007 May-Jun; 30(4):417-24. PMID: 17457216.
      View in: PubMed
    124. Leppert JT, Pantuck AJ, Figlin R, Belldegrun AS. The role of molecular markers in the staging of renal cell carcinoma. BJU Int. 2007 May; 99(5 Pt B):1208-11. PMID: 17441912.
      View in: PubMed
    125. Lam JS, Klatte T, Patard JJ, Goel RH, Guillè F, Lobel B, Abbou CC, De La Taille A, Tostain J, Cindolo L, Altieri V, Ficarra V, Artibani W, Prayer-Galetti T, Schips L, Zigeuner R, Pantuck AJ, Figlin R, Belldegrun AS. Prognostic relevance of tumour size in T3a renal cell carcinoma: a multicentre experience. Eur Urol. 2007 Jul; 52(1):155-62. PMID: 17316970.
      View in: PubMed
    126. Klatte T, Chung J, Leppert JT, Lam JS, Pantuck AJ, Figlin R, Belldegrun AS. Prognostic relevance of capsular involvement and collecting system invasion in stage I and II renal cell carcinoma. BJU Int. 2007 Apr; 99(4):821-4. PMID: 17244281.
      View in: PubMed
    127. Atkins MB, Ernstoff MS, Figlin R, Flaherty KT, George DJ, Kaelin WG, Kwon ED, Libermann TA, Linehan WM, McDermott DF, Ochoa AC, Pantuck AJ, Rini BI, Rosen MA, Sosman JA, Sukhatme VP, Vieweg JW, Wood CG, King L. Innovations and challenges in renal cell carcinoma: summary statement from the Second Cambridge Conference. Clin Cancer Res. 2007 Jan 15; 13(2 Pt 2):667s-670s. PMID: 17255291.
      View in: PubMed
    128. Lam JS, Pantuck AJ, Belldegrun AS, Figlin R. Protein expression profiles in renal cell carcinoma: staging, prognosis, and patient selection for clinical trials. Clin Cancer Res. 2007 Jan 15; 13(2 Pt 2):703s-708s. PMID: 17255297.
      View in: PubMed
    129. Pantuck AJ, Belldegrun AS, Figlin R. Cytoreductive nephrectomy for metastatic renal cell carcinoma: is it still imperative in the era of targeted therapy? Clin Cancer Res. 2007 Jan 15; 13(2 Pt 2):693s-696s. PMID: 17255295.
      View in: PubMed
    130. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, Chen I, Bycott PW, Baum CM, Figlin R. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007 Jan 11; 356(2):115-24. PMID: 17215529.
      View in: PubMed
    131. Xiao GS, Jin YS, Lu QY, Zhang ZF, Belldegrun A, Figlin R, Pantuck A, Yen Y, Li F, Rao J. Annexin-I as a potential target for green tea extract induced actin remodeling. Int J Cancer. 2007 Jan 01; 120(1):111-20. PMID: 17019707.
      View in: PubMed
    132. Weiss RH, Borowsky AD, Seligson D, Lin PY, Dillard-Telm L, Belldegrun AS, Figlin R, Pantuck AD. p21 is a prognostic marker for renal cell carcinoma: implications for novel therapeutic approaches. J Urol. 2007 Jan; 177(1):63-8; discussion 68-9. PMID: 17162001.
      View in: PubMed
    133. Weber WA, Figlin R. Monitoring cancer treatment with PET/CT: does it make a difference? J Nucl Med. 2007 Jan; 48 Suppl 1:36S-44S. PMID: 17204719.
      View in: PubMed
    134. Figlin R. Newly approved therapies for RCC and their effect on the standard of care. Clin Adv Hematol Oncol. 2007 Jan; 5(1):35-6, 66. PMID: 17339824.
      View in: PubMed
    135. Lam JS, Breda A, Belldegrun AS, Figlin R. Evolving principles of surgical management and prognostic factors for outcome in renal cell carcinoma. J Clin Oncol. 2006 Dec 10; 24(35):5565-75. PMID: 17158542.
      View in: PubMed
    136. Halbert RJ, Figlin R, Atkins MB, Bernal M, Hutson TE, Uzzo RG, Bukowski RM, Khan KD, Wood CG, Dubois RW. Treatment of patients with metastatic renal cell cancer: a RAND Appropriateness Panel. Cancer. 2006 Nov 15; 107(10):2375-83. PMID: 17048248.
      View in: PubMed
    137. Shvarts O, Janzen N, Lam JS, Leppert JT, Caliliw R, Figlin R, Belldegrun AS, Zeng G. RENCA/carbonic anhydrase-IX: a murine model of a carbonic anhydrase-IX-expressing renal cell carcinoma. Urology. 2006 Nov; 68(5):1132-8. PMID: 17095063.
      View in: PubMed
    138. Shuch BM, Lam JS, Belldegrun AS, Figlin R. Prognostic factors in renal cell carcinoma. Semin Oncol. 2006 Oct; 33(5):563-75. PMID: 17045085.
      View in: PubMed
    139. Pantuck AJ, Thomas G, Belldegrun AS, Figlin R. Mammalian target of rapamycin inhibitors in renal cell carcinoma: current status and future applications. Semin Oncol. 2006 Oct; 33(5):607-13. PMID: 17045090.
      View in: PubMed
    140. Figlin R. Renal cell carcinoma: the translation of biology to clinical application. Semin Oncol. 2006 Oct; 33(5):525-6. PMID: 17045080.
      View in: PubMed
    141. Ross HJ, Hart LL, Swanson PM, Rarick MU, Figlin R, Jacobs AD, McCune DE, Rosenberg AH, Baron AD, Grove LE, Thorn MD, Miller DM, Drachman JG, Rudin CM. A randomized, multicenter study to determine the safety and efficacy of the immunoconjugate SGN-15 plus docetaxel for the treatment of non-small cell lung carcinoma. Lung Cancer. 2006 Oct; 54(1):69-77. PMID: 16934909; PMCID: PMC3715069.
    142. Jin Y, Iwata KK, Belldegrun A, Figlin R, Pantuck A, Zhang ZF, Lieberman R, Rao J. Effect of an epidermal growth factor receptor tyrosine kinase inhibitor on actin remodeling in an in vitro bladder cancer carcinogenesis model. Mol Cancer Ther. 2006 Jul; 5(7):1754-63. PMID: 16891461.
      View in: PubMed
    143. Reckamp KL, Krysan K, Morrow JD, Milne GL, Newman RA, Tucker C, Elashoff RM, Dubinett SM, Figlin R. A phase I trial to determine the optimal biological dose of celecoxib when combined with erlotinib in advanced non-small cell lung cancer. Clin Cancer Res. 2006 Jun 01; 12(11 Pt 1):3381-8. PMID: 16740761.
      View in: PubMed
    144. Lam JS, Belldegrun AS, Figlin R. Adjuvant treatment for renal cell carcinoma. Expert Opin Pharmacother. 2006 Apr; 7(6):705-20. PMID: 16556087.
      View in: PubMed
    145. Chin AI, Lam JS, Figlin R, Belldegrun AS. Surveillance strategies for renal cell carcinoma patients following nephrectomy. Rev Urol. 2006; 8(1):1-7. PMID: 16985554; PMCID: PMC1471767.
    146. Motzer RJ, Michaelson MD, Redman BG, Hudes GR, Wilding G, Figlin R, Ginsberg MS, Kim ST, Baum CM, DePrimo SE, Li JZ, Bello CL, Theuer CP, George DJ, Rini BI. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol. 2006 Jan 01; 24(1):16-24. PMID: 16330672.
      View in: PubMed
    147. Cao W, Cai L, Rao JY, Pantuck A, Lu ML, Dalbagni G, Reuter V, Scher H, Cordon-Cardo C, Figlin R, Belldegrun A, Zhang ZF. Tobacco smoking, GSTP1 polymorphism, and bladder carcinoma. Cancer. 2005 Dec 01; 104(11):2400-8. PMID: 16240451.
      View in: PubMed
    148. Lam JS, Leppert JT, Figlin R, Belldegrun AS. Role of molecular markers in the diagnosis and therapy of renal cell carcinoma. Urology. 2005 Nov; 66(5 Suppl):1-9. PMID: 16194700.
      View in: PubMed
    149. Mestas J, Burdick MD, Reckamp K, Pantuck A, Figlin R, Strieter RM. The role of CXCR2/CXCR2 ligand biological axis in renal cell carcinoma. J Immunol. 2005 Oct 15; 175(8):5351-7. PMID: 16210641.
      View in: PubMed
    150. Lam JS, Leppert JT, Belldegrun AS, Figlin R. Adjuvant therapy of renal cell carcinoma: patient selection and therapeutic options. BJU Int. 2005 Sep; 96(4):483-8. PMID: 16104896.
      View in: PubMed
    151. Lam JS, Shvarts O, Leppert JT, Pantuck AJ, Figlin R, Belldegrun AS. Postoperative surveillance protocol for patients with localized and locally advanced renal cell carcinoma based on a validated prognostic nomogram and risk group stratification system. J Urol. 2005 Aug; 174(2):466-72; discussion 472; quiz 801. PMID: 16006866.
      View in: PubMed
    152. Leppert JT, Lam JS, Pantuck AJ, Figlin R, Belldegrun AS. Carbonic anhydrase IX and the future of molecular markers in renal cell carcinoma. BJU Int. 2005 Aug; 96(3):281-5. PMID: 16042714.
      View in: PubMed
    153. Truell JS, Fishbein MC, Figlin R. Myocarditis temporally related to the use of gefitinib (Iressa). Arch Pathol Lab Med. 2005 Aug; 129(8):1044-6. PMID: 16048398.
      View in: PubMed
    154. Yang XJ, Tan MH, Kim HL, Ditlev JA, Betten MW, Png CE, Kort EJ, Futami K, Furge KA, Takahashi M, Kanayama HO, Tan PH, Teh BS, Luan C, Wang K, Pins M, Tretiakova M, Anema J, Kahnoski R, Nicol T, Stadler W, Vogelzang NG, Amato R, Seligson D, Figlin R, Belldegrun A, Rogers CG, Teh BT. A molecular classification of papillary renal cell carcinoma. Cancer Res. 2005 Jul 01; 65(13):5628-37. PMID: 15994935.
      View in: PubMed
    155. Garland L, Gitlitz B, Ebbinghaus S, Pan H, de Haan H, Puri RK, Von Hoff D, Figlin R. Phase I trial of intravenous IL-4 pseudomonas exotoxin protein (NBI-3001) in patients with advanced solid tumors that express the IL-4 receptor. J Immunother. 2005 Jul-Aug; 28(4):376-81. PMID: 16000956.
      View in: PubMed
    156. Lam JS, Shvarts O, Said JW, Pantuck AJ, Seligson DB, Aldridge ME, Bui MH, Liu X, Horvath S, Figlin R, Belldegrun AS. Clinicopathologic and molecular correlations of necrosis in the primary tumor of patients with renal cell carcinoma. Cancer. 2005 Jun 15; 103(12):2517-25. PMID: 15880379.
      View in: PubMed
    157. Lam JS, Shvarts O, Leppert JT, Figlin R, Belldegrun AS. Renal cell carcinoma 2005: new frontiers in staging, prognostication and targeted molecular therapy. J Urol. 2005 Jun; 173(6):1853-62. PMID: 15879764.
      View in: PubMed
    158. Kim HL, Seligson D, Liu X, Janzen N, Bui MH, Yu H, Shi T, Belldegrun AS, Horvath S, Figlin R. Using tumor markers to predict the survival of patients with metastatic renal cell carcinoma. J Urol. 2005 May; 173(5):1496-501. PMID: 15821467.
      View in: PubMed
    159. Patard JJ, Leray E, Rioux-Leclercq N, Cindolo L, Ficarra V, Zisman A, De La Taille A, Tostain J, Artibani W, Abbou CC, Lobel B, Guillé F, Chopin DK, Mulders PF, Wood CG, Swanson DA, Figlin R, Belldegrun AS, Pantuck AJ. Prognostic value of histologic subtypes in renal cell carcinoma: a multicenter experience. J Clin Oncol. 2005 Apr 20; 23(12):2763-71. PMID: 15837991.
      View in: PubMed
    160. Lam JS, Leppert JT, Belldegrun AS, Figlin R. Novel approaches in the therapy of metastatic renal cell carcinoma. World J Urol. 2005 Jul; 23(3):202-12. PMID: 15812574.
      View in: PubMed
    161. Lam JS, Pantuck AJ, Belldegrun AS, Figlin R. G250: a carbonic anhydrase IX monoclonal antibody. Curr Oncol Rep. 2005 Mar; 7(2):109-15. PMID: 15717944.
      View in: PubMed
    162. Shvarts O, Seligson D, Lam J, Shi T, Horvath S, Figlin R, Belldegrun A, Pantuck AJ. p53 is an independent predictor of tumor recurrence and progression after nephrectomy in patients with localized renal cell carcinoma. J Urol. 2005 Mar; 173(3):725-8. PMID: 15711252.
      View in: PubMed
    163. Lu QY, Jin YS, Pantuck A, Zhang ZF, Heber D, Belldegrun A, Brooks M, Figlin R, Rao J. Green tea extract modulates actin remodeling via Rho activity in an in vitro multistep carcinogenic model. Clin Cancer Res. 2005 Feb 15; 11(4):1675-83. PMID: 15746073.
      View in: PubMed
    164. Lam JS, Leppert JT, Figlin R, Belldegrun AS. Surveillance following radical or partial nephrectomy for renal cell carcinoma. Curr Urol Rep. 2005 Feb; 6(1):7-18. PMID: 15610692.
      View in: PubMed
    165. Lam JS, Belldegrun AS, Figlin R. Advances in immune-based therapies of renal cell carcinoma. Expert Rev Anticancer Ther. 2004 Dec; 4(6):1081-96. PMID: 15606335.
      View in: PubMed
    166. Patard JJ, Dorey FJ, Cindolo L, Ficarra V, De La Taille A, Tostain J, Artibani W, Abbou CC, Lobel B, Chopin DK, Figlin R, Belldegrun AS, Pantuck AJ. Symptoms as well as tumor size provide prognostic information on patients with localized renal tumors. J Urol. 2004 Dec; 172(6 Pt 1):2167-71. PMID: 15538224.
      View in: PubMed
    167. Atkins MB, Avigan DE, Bukowski RM, Childs RW, Dutcher JP, Eisen TG, Figlin R, Finke JH, Flanigan RC, George DJ, Goldberg SN, Gordon MS, Iliopoulos O, Kaelin WG, Linehan WM, Lipton A, Motzer RJ, Novick AC, Stadler WM, Teh BT, Yang JC, King L. Innovations and challenges in renal cancer: consensus statement from the first international conference. Clin Cancer Res. 2004 Sep 15; 10(18 Pt 2):6277S-81S. PMID: 15448017.
      View in: PubMed
    168. Lam JS, Belldegrun AS, Figlin R. Tissue array-based predictions of pathobiology, prognosis, and response to treatment for renal cell carcinoma therapy. Clin Cancer Res. 2004 Sep 15; 10(18 Pt 2):6304S-9S. PMID: 15448022.
      View in: PubMed
    169. Shvarts O, Lam JS, Kim HL, Han KR, Figlin R, Belldegrun A. Eastern Cooperative Oncology Group performance status predicts bone metastasis in patients presenting with renal cell carcinoma: implication for preoperative bone scans. J Urol. 2004 Sep; 172(3):867-70. PMID: 15310985.
      View in: PubMed
    170. Han KR, Janzen NK, McWhorter VC, Kim HL, Pantuck AJ, Zisman A, Figlin R, Dorey FJ, Said JW, Belldegrun AS. Cystic renal cell carcinoma: biology and clinical behavior. Urol Oncol. 2004 Sep-Oct; 22(5):410-4. PMID: 15464922.
      View in: PubMed
    171. Figlin R, Alvin H, Meinhardt CL. Target-specific therapy requires target-specific populations in the treatment of renal cell carcinoma. Urologe A. 2004 Sep; 43 Suppl 3:S144-5. PMID: 15179554.
      View in: PubMed
    172. Kim HL, Seligson D, Liu X, Janzen N, Bui MH, Yu H, Shi T, Figlin R, Horvath S, Belldegrun AS. Using protein expressions to predict survival in clear cell renal carcinoma. Clin Cancer Res. 2004 Aug 15; 10(16):5464-71. PMID: 15328185.
      View in: PubMed
    173. Patard JJ, Kim HL, Lam JS, Dorey FJ, Pantuck AJ, Zisman A, Ficarra V, Han KR, Cindolo L, De La Taille A, Tostain J, Artibani W, Dinney CP, Wood CG, Swanson DA, Abbou CC, Lobel B, Mulders PF, Chopin DK, Figlin R, Belldegrun AS. Use of the University of California Los Angeles integrated staging system to predict survival in renal cell carcinoma: an international multicenter study. J Clin Oncol. 2004 Aug 15; 22(16):3316-22. PMID: 15310775.
      View in: PubMed
    174. Rowinsky EK, Schwartz GH, Gollob JA, Thompson JA, Vogelzang NJ, Figlin R, Bukowski R, Haas N, Lockbaum P, Li YP, Arends R, Foon KA, Schwab G, Dutcher J. Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer. J Clin Oncol. 2004 Aug 01; 22(15):3003-15. PMID: 15210739.
      View in: PubMed
    175. Patard JJ, Shvarts O, Lam JS, Pantuck AJ, Kim HL, Ficarra V, Cindolo L, Han KR, De La Taille A, Tostain J, Artibani W, Abbou CC, Lobel B, Chopin DK, Figlin R, Mulders PF, Belldegrun AS. Safety and efficacy of partial nephrectomy for all T1 tumors based on an international multicenter experience. J Urol. 2004 Jun; 171(6 Pt 1):2181-5, quiz 2435. PMID: 15126781.
      View in: PubMed
    176. Bui MH, Visapaa H, Seligson D, Kim H, Han KR, Huang Y, Horvath S, Stanbridge EJ, Palotie A, Figlin R, Belldegrun AS. Prognostic value of carbonic anhydrase IX and KI67 as predictors of survival for renal clear cell carcinoma. J Urol. 2004 Jun; 171(6 Pt 1):2461-6. PMID: 15126876.
      View in: PubMed
    177. Riedl K, Krysan K, Põld M, Dalwadi H, Heuze-Vourc'h N, Dohadwala M, Liu M, Cui X, Figlin R, Mao JT, Strieter R, Sharma S, Dubinett SM. Multifaceted roles of cyclooxygenase-2 in lung cancer. Drug Resist Updat. 2004 Jun; 7(3):169-84. PMID: 15296859.
      View in: PubMed
    178. Suh RD, Goldin JG, Wallace AB, Sheehan RE, Heinze SB, Gitlitz BJ, Figlin R. Metastatic renal cell carcinoma: CT-guided immunotherapy as a technically feasible and safe approach to delivery of gene therapy for treatment. Radiology. 2004 May; 231(2):359-64. PMID: 15128982.
      View in: PubMed
    179. Kim HL, Han KR, Zisman A, Figlin R, Belldegrun AS. Cachexia-like symptoms predict a worse prognosis in localized t1 renal cell carcinoma. J Urol. 2004 May; 171(5):1810-3. PMID: 15076282.
      View in: PubMed
    180. Han KR, Kim HL, Pantuck AJ, Dorey FJ, Figlin R, Belldegrun AS. Use of American Society of Anesthesiologists physical status classification to assess perioperative risk in patients undergoing radical nephrectomy for renal cell carcinoma. Urology. 2004 May; 63(5):841-6; discussion 846-7. PMID: 15134960.
      View in: PubMed
    181. Pantuck AJ, van Ophoven A, Gitlitz BJ, Tso CL, Acres B, Squiban P, Ross ME, Belldegrun AS, Figlin R. Phase I trial of antigen-specific gene therapy using a recombinant vaccinia virus encoding MUC-1 and IL-2 in MUC-1-positive patients with advanced prostate cancer. J Immunother. 2004 May-Jun; 27(3):240-53. PMID: 15076142.
      View in: PubMed
    182. Seligson DB, Pantuck AJ, Liu X, Huang Y, Horvath S, Bui MH, Han KR, Correa AJ, Eeva M, Tze S, Belldegrun AS, Figlin R. Epithelial cell adhesion molecule (KSA) expression: pathobiology and its role as an independent predictor of survival in renal cell carcinoma. Clin Cancer Res. 2004 Apr 15; 10(8):2659-69. PMID: 15102668.
      View in: PubMed
    183. Foon KA, Yang XD, Weiner LM, Belldegrun AS, Figlin R, Crawford J, Rowinsky EK, Dutcher JP, Vogelzang NJ, Gollub J, Thompson JA, Schwartz G, Bukowski RM, Roskos LK, Schwab GM. Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibody. Int J Radiat Oncol Biol Phys. 2004 Mar 01; 58(3):984-90. PMID: 14967460.
      View in: PubMed
    184. Mukouyama H, Janzen NK, Hernandez JM, Lam JS, Caliliw R, Wang AY, Figlin R, Belldegrun AS, Zeng G. Generation of kidney cancer-specific antitumor immune responses using peripheral blood monocytes transduced with a recombinant adenovirus encoding carbonic anhydrase 9. Clin Cancer Res. 2004 Feb 15; 10(4):1421-9. PMID: 14977845.
      View in: PubMed
    185. Kim HL, Zisman A, Han KR, Figlin R, Belldegrun AS. Prognostic significance of venous thrombus in renal cell carcinoma. Are renal vein and inferior vena cava involvement different? J Urol. 2004 Feb; 171(2 Pt 1):588-91. PMID: 14713765.
      View in: PubMed
    186. Shvarts O, Lam J, Figlin R, Belldegrun AS. Heat shock-peptide complex vaccine as adjuvant therapy for high-risk patients with resected renal cell carcinoma. Curr Urol Rep. 2004 Feb; 5(1):11-2. PMID: 14733830.
      View in: PubMed
    187. Leibovich BC, Han KR, Bui MH, Pantuck AJ, Dorey FJ, Figlin R, Belldegrun A. Scoring algorithm to predict survival after nephrectomy and immunotherapy in patients with metastatic renal cell carcinoma: a stratification tool for prospective clinical trials. Cancer. 2003 Dec 15; 98(12):2566-75. PMID: 14669275.
      View in: PubMed
    188. Han KR, Bleumer I, Pantuck AJ, Kim HL, Dorey FJ, Janzen NK, Zisman A, Dinney CP, Wood CG, Swanson DA, Said JW, Figlin R, Mulders PF, Belldegrun AS. Validation of an integrated staging system toward improved prognostication of patients with localized renal cell carcinoma in an international population. J Urol. 2003 Dec; 170(6 Pt 1):2221-4. PMID: 14634383.
      View in: PubMed
    189. Riedl K, Baratelli F, Batra RK, Yang SC, Luo J, Escuadro B, Figlin R, Strieter R, Sharma S, Dubinett S. Overexpression of CCL-21/secondary lymphoid tissue chemokine in human dendritic cells augments chemotactic activities for lymphocytes and antigen presenting cells. Mol Cancer. 2003 Nov 02; 2:35. PMID: 14613584; PMCID: PMC270078.
    190. Kim HL, Belldegrun AS, Freitas DG, Bui MH, Han KR, Dorey FJ, Figlin R. Paraneoplastic signs and symptoms of renal cell carcinoma: implications for prognosis. J Urol. 2003 Nov; 170(5):1742-6. PMID: 14532767.
      View in: PubMed
    191. Janzen NK, Kim HL, Figlin R, Belldegrun AS. Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease. Urol Clin North Am. 2003 Nov; 30(4):843-52. PMID: 14680319.
      View in: PubMed
    192. Gitlitz BJ, Baker C, Chapman Y, Allen HJ, Bosserman LD, Patel R, Sanchez JD, Shapiro RM, Figlin R. A phase II study of gemcitabine and docetaxel therapy in patients with advanced urothelial carcinoma. Cancer. 2003 Nov 01; 98(9):1863-9. PMID: 14584068.
      View in: PubMed
    193. Kiertscher SM, Gitlitz BJ, Figlin R, Roth MD. Granulocyte/macrophage-colony stimulating factor and interleukin-4 expand and activate type-1 dendritic cells (DC1) when administered in vivo to cancer patients. Int J Cancer. 2003 Nov 01; 107(2):256-61. PMID: 12949803.
      View in: PubMed
    194. Pantuck AJ, Zeng G, Belldegrun AS, Figlin R. Pathobiology, prognosis, and targeted therapy for renal cell carcinoma: exploiting the hypoxia-induced pathway. Clin Cancer Res. 2003 Oct 15; 9(13):4641-52. PMID: 14581333.
      View in: PubMed
    195. Thompson JA, Figlin R, Sifri-Steele C, Berenson RJ, Frohlich MW. A phase I trial of CD3/CD28-activated T cells (Xcellerated T cells) and interleukin-2 in patients with metastatic renal cell carcinoma. Clin Cancer Res. 2003 Sep 01; 9(10 Pt 1):3562-70. PMID: 14506142.
      View in: PubMed
    196. Palapattu GS, Pantuck AJ, Dorey F, Said JW, Figlin R, Belldegrun AS. Collecting system invasion in renal cell carcinoma: impact on prognosis and future staging strategies. J Urol. 2003 Sep; 170(3):768-72; discussion 772. PMID: 12913694.
      View in: PubMed
    197. Gitlitz BJ, Belldegrun AS, Zisman A, Chao DH, Pantuck AJ, Hinkel A, Mulders P, Moldawer N, Tso CL, Figlin R. A pilot trial of tumor lysate-loaded dendritic cells for the treatment of metastatic renal cell carcinoma. J Immunother. 2003 Sep-Oct; 26(5):412-9. PMID: 12973030.
      View in: PubMed
    198. Gitlitz BJ, Figlin R. Cytokine-based therapy for metastatic renal cell cancer. Urol Clin North Am. 2003 Aug; 30(3):589-600. PMID: 12953757.
      View in: PubMed
    199. Leibovich BC, Pantuck AJ, Bui MH, Ryu-Han K, Zisman A, Figlin R, Belldegrun A. Current staging of renal cell carcinoma. Urol Clin North Am. 2003 Aug; 30(3):481-97, viii. PMID: 12953750.
      View in: PubMed
    200. Rochlitz C, Figlin R, Squiban P, Salzberg M, Pless M, Herrmann R, Tartour E, Zhao Y, Bizouarne N, Baudin M, Acres B. Phase I immunotherapy with a modified vaccinia virus (MVA) expressing human MUC1 as antigen-specific immunotherapy in patients with MUC1-positive advanced cancer. J Gene Med. 2003 Aug; 5(8):690-9. PMID: 12898638.
      View in: PubMed
    201. Clark JI, Atkins MB, Urba WJ, Creech S, Figlin R, Dutcher JP, Flaherty L, Sosman JA, Logan TF, White R, Weiss GR, Redman BG, Tretter CP, McDermott D, Smith JW, Gordon MS, Margolin KA. Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: a cytokine working group randomized trial. J Clin Oncol. 2003 Aug 15; 21(16):3133-40. PMID: 12810695.
      View in: PubMed
    202. Pantuck AJ, Zisman A, Dorey F, Chao DH, Han KR, Said J, Gitlitz B, Belldegrun AS, Figlin R. Renal cell carcinoma with retroperitoneal lymph nodes. Impact on survival and benefits of immunotherapy. Cancer. 2003 Jun 15; 97(12):2995-3002. PMID: 12784334.
      View in: PubMed
    203. Pantuck AJ, Zisman A, Dorey F, Chao DH, Han KR, Said J, Gitlitz BJ, Figlin R, Belldegrun AS. Renal cell carcinoma with retroperitoneal lymph nodes: role of lymph node dissection. J Urol. 2003 Jun; 169(6):2076-83. PMID: 12771723.
      View in: PubMed
    204. Hernández JM, Bui MH, Han KR, Mukouyama H, Freitas DG, Nguyen D, Caliliw R, Shintaku PI, Paik SH, Tso CL, Figlin R, Belldegrun AS. Novel kidney cancer immunotherapy based on the granulocyte-macrophage colony-stimulating factor and carbonic anhydrase IX fusion gene. Clin Cancer Res. 2003 May; 9(5):1906-16. PMID: 12738749.
      View in: PubMed
    205. Visapää H, Bui M, Huang Y, Seligson D, Tsai H, Pantuck A, Figlin R, Rao JY, Belldegrun A, Horvath S, Palotie A. Correlation of Ki-67 and gelsolin expression to clinical outcome in renal clear cell carcinoma. Urology. 2003 Apr; 61(4):845-50. PMID: 12670587.
      View in: PubMed
    206. Gitlitz BJ, Figlin R, Kiertscher SM, Moldawer N, Rosen F, Roth MD. Phase I trial of granulocyte macrophage-colony stimulating factor and interleukin-4 as a combined immunotherapy for patients with cancer. J Immunother. 2003 Mar-Apr; 26(2):171-8. PMID: 12616109.
      View in: PubMed
    207. Han KR, Bui MH, Pantuck AJ, Freitas DG, Leibovich BC, Dorey FJ, Zisman A, Janzen NK, Mukouyama H, Figlin R, Belldegrun AS. TNM T3a renal cell carcinoma: adrenal gland involvement is not the same as renal fat invasion. J Urol. 2003 Mar; 169(3):899-903; discussion 903-4. PMID: 12576809.
      View in: PubMed
    208. Zisman A, Wieder JA, Pantuck AJ, Chao DH, Dorey F, Said JW, Gitlitz BJ, deKernion JB, Figlin R, Belldegrun AS. Renal cell carcinoma with tumor thrombus extension: biology, role of nephrectomy and response to immunotherapy. J Urol. 2003 Mar; 169(3):909-16. PMID: 12576811.
      View in: PubMed
    209. Han KR, Pantuck AJ, Bui MH, Shvarts O, Freitas DG, Zisman A, Leibovich BC, Dorey FJ, Gitlitz BJ, Figlin R, Belldegrun AS. Number of metastatic sites rather than location dictates overall survival of patients with node-negative metastatic renal cell carcinoma. Urology. 2003 Feb; 61(2):314-9. PMID: 12597937.
      View in: PubMed
    210. Kim HL, Belldegrun AS, Figlin R. Immune gene therapy for kidney cancer: the search for a magic trigger. Mol Ther. 2003 Feb; 7(2):153-4. PMID: 12597902.
      View in: PubMed
    211. Bui MH, Seligson D, Han KR, Pantuck AJ, Dorey FJ, Huang Y, Horvath S, Leibovich BC, Chopra S, Liao SY, Stanbridge E, Lerman MI, Palotie A, Figlin R, Belldegrun AS. Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. Clin Cancer Res. 2003 Feb; 9(2):802-11. PMID: 12576453.
      View in: PubMed
    212. Gitlitz BJ, Figlin R. Cell, gene and vaccine based strategies in kidney cancer. Cancer Treat Res. 2003; 116:183-98. PMID: 14650833.
      View in: PubMed
    213. Zisman A, Pantuck AJ, Wieder J, Chao DH, Dorey F, Said JW, deKernion JB, Figlin R, Belldegrun AS. Risk group assessment and clinical outcome algorithm to predict the natural history of patients with surgically resected renal cell carcinoma. J Clin Oncol. 2002 Dec 01; 20(23):4559-66. PMID: 12454113.
      View in: PubMed
    214. Zisman A, Chao DH, Pantuck AJ, Kim HJ, Wieder JA, Figlin R, Said JW, Belldegrun AS. Unclassified renal cell carcinoma: clinical features and prognostic impact of a new histological subtype. J Urol. 2002 Sep; 168(3):950-5. PMID: 12187197.
      View in: PubMed
    215. Zisman A, Pantuck AJ, Chao DH, Wieder JA, Dorey F, Said JW, Kernion JB, Figlin R, Belldegrun AS. Renal cell carcinoma with tumor thrombus: is cytoreductive nephrectomy for advanced disease associated with an increased complication rate? J Urol. 2002 Sep; 168(3):962-7. PMID: 12187200.
      View in: PubMed
    216. Zisman A, Pantuck AJ, Dorey F, Chao DH, Gitlitz BJ, Moldawer N, Lazarovici D, deKernion JB, Figlin R, Belldegrun AS. Mathematical model to predict individual survival for patients with renal cell carcinoma. J Clin Oncol. 2002 Mar 01; 20(5):1368-74. PMID: 11870181.
      View in: PubMed
    217. Chao D, Zisman A, Pantuck AJ, Gitlitz BJ, Freedland SJ, Said JW, Figlin R, Belldegrun AS. Collecting duct renal cell carcinoma: clinical study of a rare tumor. J Urol. 2002 Jan; 167(1):71-4. PMID: 11743278.
      View in: PubMed
    218. Figlin R, Thompson JA, Bukowski RM, Vogelzang NJ, Novick AC, Lange P, Steinberg GD, Belldegrun AS. Multicenter, randomized, phase III trial of CD8(+) tumor-infiltrating lymphocytes in combination with recombinant interleukin-2 in metastatic renal cell carcinoma. J Clin Oncol. 1999 Aug; 17(8):2521-9. PMID: 10561318.
      View in: PubMed
    219. Figlin R, Parker SE, Horton HM. Technology evaluation: interleukin-2 gene therapy for the treatment of renal cell carcinoma. Curr Opin Mol Ther. 1999 Apr; 1(2):271-8. PMID: 11715951.
      View in: PubMed
    Robert's Networks
    Concepts
    Derived automatically from this person's publications.
    _
    Co-Authors
    People in Profiles who have published with this person.
    _
    Related Authors
    People who share related concepts with this person.
    _